DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
lenacapavir - 2 ” - 2 Dr - 2 Sanjay Gupta - 2 Gilead - 2 Onyema Ogbuagu - 1 It’s - 1 drugmaker Gilead - 1
Top related locs:
United States Gilead Argentina Brazil Mexico Peru South Africa Thailand
Top related orgs:
CNN - 2 CNN Health - 2 Center - 2 Gilead Sciences - 1 Yale - 1 Research - 1 World Health Organization - 1 New England - 1

Search resuls for: "drugmaker Gilead"


3 mentions found


☆ Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
  + stars: | 2024-09-12 | by ( Deidre Mcphillips | ) edition.cnn.com   time to read: +2 min
CNN —A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP. In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead Sciences. There were only two cases among 2,180 patients – effectively reducing the risk of HIV infection by 96% and proving 89% more effective than Truvada, a pill taken once a day. It’s a “significant breakthrough in HIV prevention,” according to a news release from the World Health Organization in July. Gilead said it will use these trial data to start the drug approval process in multiple countries by the end of the year.
Persons: lenacapavir, ”, Onyema Ogbuagu, Dr, Sanjay Gupta, It’s, Gilead Organizations: CNN, Gilead Sciences, Yale, Research, CNN Health, World Health Organization Locations: Gilead, Argentina, Brazil, Mexico, Peru, South Africa, Thailand, United States, Africa
☆ Twice-yearly shot proves successful at preventing HIV infection among women, trial data shows
  + stars: | 2024-07-24 | by ( Jacqueline Howard | ) edition.cnn.com   time to read: +9 min
CNN —Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa. The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and published Wednesday in the New England Journal of Medicine. The twice-a-year injections of lenacapavir could add another option at preventing HIV infections to the toolbox. The latest Phase 3 findings are part of Gilead’s PURPOSE program, which comprises five HIV prevention trials around the world. “While Gilead awaits additional phase 3 clinical trial data and the potential regulatory filings for HIV prevention administered twice-yearly, it is too early to state the price of lenacapavir for PrEP (prevention).
Persons: drugmaker Gilead, ” Linda, Gail Bekker, Desmond Tutu, “, ”, Dan Barouch, hasn’t, Gilead, Dr, Jason Zucker, Barouch, ” Zucker, Lenacapavir, Gilead spokeperson, lenacapavir, Sanjay Gupta, Daniel O’Day Organizations: CNN, New England, of Medicine, International AIDS, PrEP, University of Cape, International AIDS Society, Center, Virology, Vaccine, Beth Israel Deaconess Medical, United, lenacapavir, Columbia University Irving Medical Center, ”, US Food and Drug Administration, AIDS, CNN Health, People’s Medicines Alliance, Medicines Locations: Africa, Munich, University of Cape Town, South Africa, Uganda, Argentina, Brazil, Mexico, Peru, Thailand, United States, United Kingdom, Germany, Gilead, Europe
☆ U.S. Lags Behind Other Countries in Hepatitis-C Treatment
  + stars: | 2024-04-28 | by ( Ted Alcorn | ) www.nytimes.com   time to read: 1 min
In the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave of new therapies have been used to cure millions of people around the world of the blood-borne virus. Today, 15 countries, including Egypt, Canada and Australia, are on track to eliminate hepatitis C during this decade, according to the Center for Disease Analysis Foundation, a nonprofit. Each has pursued a dogged national screening and treatment campaign. Spread through the blood including IV drug use, hepatitis C causes liver inflammation, though people may not display symptoms for years. Only a fraction of Americans with the virus are aware of the infection, even as many develop the fatal disease.
Organizations: Center, Disease Analysis Locations: Egypt, Canada, Australia, United States
0 next >>
Total: 3